Study: NCT06507605

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R21
Description: R21 is a portion of Pf circumsporozoite protein fused with hepatitis B surface antigen in the form of non-infectious virus-like particles (VLPs) produced in yeast cells (Hansenula) by recombinant DNA technology.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R21
Description: R21 is a portion of Pf circumsporozoite protein fused with hepatitis B surface antigen in the form of non-infectious virus-like particles (VLPs) produced in yeast cells (Hansenula) by recombinant DNA technology.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfs230D1-CRM197
Description: Recombinant Pfs230 domain 1 (Pfs230D1; a subdomain of a surface antigen of gametocytes, gametes, and zygotes, in the mosquito stage of Pf conjugated to CRM197 and adjuvanted with 50μg of Matrix-M.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfs230D1-CRM197
Description: Recombinant Pfs230 domain 1 (Pfs230D1; a subdomain of a surface antigen of gametocytes, gametes, and zygotes, in the mosquito stage of Pf conjugated to CRM197 and adjuvanted with 50μg of Matrix-M.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfs230D1-CRM197
Description: Recombinant Pfs230 domain 1 (Pfs230D1; a subdomain of a surface antigen of gametocytes, gametes, and zygotes, in the mosquito stage of Pf conjugated to CRM197 and adjuvanted with 50μg of Matrix-M.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfs230D1-CRM197
Description: Recombinant Pfs230 domain 1 (Pfs230D1; a subdomain of a surface antigen of gametocytes, gametes, and zygotes, in the mosquito stage of Pf conjugated to CRM197 and adjuvanted with 50μg of Matrix-M.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfs230D1-CRM197
Description: Recombinant Pfs230 domain 1 (Pfs230D1; a subdomain of a surface antigen of gametocytes, gametes, and zygotes, in the mosquito stage of Pf conjugated to CRM197 and adjuvanted with 50μg of Matrix-M.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfs230D1-CRM197
Description: Recombinant Pfs230 domain 1 (Pfs230D1; a subdomain of a surface antigen of gametocytes, gametes, and zygotes, in the mosquito stage of Pf conjugated to CRM197 and adjuvanted with 50μg of Matrix-M.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfs230D1-CRM197
Description: Recombinant Pfs230 domain 1 (Pfs230D1; a subdomain of a surface antigen of gametocytes, gametes, and zygotes, in the mosquito stage of Pf conjugated to CRM197 and adjuvanted with 50μg of Matrix-M.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfs230D1-CRM197
Description: Recombinant Pfs230 domain 1 (Pfs230D1; a subdomain of a surface antigen of gametocytes, gametes, and zygotes, in the mosquito stage of Pf conjugated to CRM197 and adjuvanted with 50μg of Matrix-M.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfs230D1-CRM197
Description: Recombinant Pfs230 domain 1 (Pfs230D1; a subdomain of a surface antigen of gametocytes, gametes, and zygotes, in the mosquito stage of Pf conjugated to CRM197 and adjuvanted with 50μg of Matrix-M.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfs230D1-EPA
Description: Recombinant Pfs230D1 conjugated to a recombinant Pseudomonas aeruginosa ExoProtein A (EPA)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Matrix-M
Description: Vaccine adjuvant that contains purified saponin (from Quillaja saponaria Molina) and cholesterol and phosphatidyl choline. Matrix-M will be used at a 50μg dose for vaccinations.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Matrix-M
Description: Vaccine adjuvant that contains purified saponin (from Quillaja saponaria Molina) and cholesterol and phosphatidyl choline. Matrix-M will be used at a 50μg dose for vaccinations.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Matrix-M
Description: Vaccine adjuvant that contains purified saponin (from Quillaja saponaria Molina) and cholesterol and phosphatidyl choline. Matrix-M will be used at a 50μg dose for vaccinations.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Matrix-M
Description: Vaccine adjuvant that contains purified saponin (from Quillaja saponaria Molina) and cholesterol and phosphatidyl choline. Matrix-M will be used at a 50μg dose for vaccinations.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Matrix-M
Description: Vaccine adjuvant that contains purified saponin (from Quillaja saponaria Molina) and cholesterol and phosphatidyl choline. Matrix-M will be used at a 50μg dose for vaccinations.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Matrix-M
Description: Vaccine adjuvant that contains purified saponin (from Quillaja saponaria Molina) and cholesterol and phosphatidyl choline. Matrix-M will be used at a 50μg dose for vaccinations.